Perspective Therapeutics Inc. (CATX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

The Roarable RQD rating assigns a score of 37 out of 100, a letter grade of D-, and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow" (). The score is built from five pillars, each weighted at 20 points:

• Fundamental Cash Engine: 7 / 20. The pillar reflects a ROIC of -35% and an FCF yield of 0% (and market data). For a prospective investor, this means the company is not currently generating returns on invested capital, and its cash-based valuation support is effectively absent. Any upside would have to come from factors outside current cash generation.
• Whale 13F Flow: 5 / 20. This pillar captures institutional accumulation and options positioning (). The low score indicates weak institutional conviction in the data set. Institutional positioning is not a source of support here, and an investor should not assume large-holder confidence.
• Insider Conviction: 5 / 20. This pillar reflects SEC Form 4 and Congressional PTR cluster flow (). A low score signals that insider activity is not providing a confidence signal in the source data.
• Macro Regime Fit: 10 / 20. The pillar reflects a beta of 1.0 and sector sensitivity (and market data). A beta of 1.0 means the stock is expected to move in line with the broader market, which neither amplifies nor dampens market exposure in this framing. The mid-range score reflects neutral rather than favorable macro alignment.
• Forensic Balance Sheet: 10 / 20. The pillar draws on an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5 (). The Piotroski reading of 2/9 is weak, while the Z-Score and leverage figures are the more balanced components of this pillar.

Taken together, the rating points to a company with weak cash economics, limited institutional and insider endorsement, and a balance sheet that is serviceable but not strong on the forensic measures. The valuation tradeoff is that a low share price ($1.15 per market data) and a wide 52-week range ($1.06 - $6.16) can attract speculative interest, but the rating itself does not identify fundamental support for that interest. Prospective investors would need to weigh the score's emphasis on cash generation and flow against any upside thesis they hold, recognizing that catalyst-driven moves are not captured as durable value in the rating.

Perspective Therapeutics Inc. Is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile reports a market capitalization of $0.1B. Revenue is reported as — across the available periods (), indicating no reported revenue in the source data.

The company reported operating and net losses in every period shown, with operating losses widening from -$40.9M in FY 2023 to -$113.6M in FY 2025, and free cash flow remaining negative throughout. Gross, operating, and net margins are each reported as 0% (per the market data), and ROIC is -35% (per market data). Cash declined from $61.6M in FY 2024 to $30.6M in FY 2025 (). The Altman Z-Score of 2.5, Piotroski F-Score of 2/9, and Debt/Equity of 0.5 are reported in the Roarable RQD rating.

• 🐂 Primary Bull Case: BTIG reiterated a Buy rating with a $14 price target, and a November oral presentation of cancer-treatment data is scheduled as a potential near-term catalyst. With Fundamental Cash Engine at 7/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $1.06 – $6.16 52-week range.
• 🐻 Primary Bear Case: The company reported net losses of -$103.1M in FY 2025 with zero revenue, a ROIC of -35%, and cash that fell from $61.6M to $30.6M. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

No upstream or downstream dependencies, sector correlation mappings, or 2nd-order bottlenecks are available in the source data. The sector assignment (Health Care; Biotechnology: Pharmaceutical Preparations) is the only structural context provided. Investors should note that the absence of mapped supply-chain links means ripple effects from suppliers, partners, or competitors cannot be assessed from the provided data.

• Key Question #1: What drove the operating loss expansion from -$40.9M in FY 2023 to -$113.6M in FY 2025, and what is the expected cash runway given the $30.6M cash balance reported for FY 2025?
• Key Question #2: What is the basis for the divergence between BTIG's $14 price target and RBC's $4 price target?
• Key Question #3: What is the status and risk profile of the Lead 212 program referenced in the risk-watch headline?